Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR activating variants status confers therapeutic sensitivity to Erlotinib in patients with Non-Small Cell Lung Cancer.
The Republic of Ireland's Health Service Executive (HSE) has approved erlotinib for reimbursement as a treatment option for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations.
This statement is based on a regulatory approval from the Health Service Executive:
First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations